Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 17/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3382809 | 0.88 | HRH3 (1.00) | HRH3HTT | |
| SCHEMBL3380536 | 0.87 | HRH3 (1.00) | HRH3 | |
| SCHEMBL1449893 | 0.82 | HRH3 (1.00) | HRH3 | |
| SCHEMBL27657363 | 0.80 | HRH3 (0.52) | HRH3ALDH1A1NPSR1HTT | |
| SCHEMBL3382425 | 0.77 | HRH3 (0.77) | HRH3ALDH1A1NPSR1 | |
| SCHEMBL9219382 | 0.74 | HRH3 (0.62) | HRH3ALDH1A1NPSR1HTT | |
| Citric Acid SCHEMBL1450003 | 0.73 | HRH3 (0.78) | HRH3 | |
| SCHEMBL521532 | 0.71 | HRH3 (1.00) | HRH3 | |
| SCHEMBL1177694 | 0.71 | HRH3 (0.89) | HRH3 | |
| SCHEMBL3382083 | 0.70 | HRH3 (1.00) | HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771432-B1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-08 | — | — | EP | claimed |
| US-7429659-B2 | Furan compounds as histamine H3 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-30 | — | — | US | claimed |
| EP-1771432-A2 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-11 | — | — | EP | claimed |
| WO-2005096734-A2 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-10-20 | — | — | WO | claimed |
| US-20050222129-A1 | Non-imidazole heterocyclic compounds | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2005-10-06 | — | — | US | claimed |
| EP-1771432-B1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-08 | — | — | EP | disclosed |
| EP-1771432-B1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-08 | — | — | EP | disclosed |
| US-20080317671-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | CARRUTHERS NICHOLAS I | 2008-12-25 | — | — | US | disclosed |
| US-20080317671-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | CARRUTHERS NICHOLAS I | 2008-12-25 | — | — | US | disclosed |
| US-20080317671-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | CARRUTHERS NICHOLAS I | 2008-12-25 | — | — | US | disclosed |
| US-7429659-B2 | Furan compounds as histamine H3 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-30 | — | — | US | disclosed |
| US-7429659-B2 | Furan compounds as histamine H3 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-30 | — | — | US | disclosed |
| US-7429659-B2 | Furan compounds as histamine H3 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-30 | — | — | US | disclosed |
| WO-2005096734-A2 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-10-20 | — | — | WO | disclosed |
| US-20050222129-A1 | Non-imidazole heterocyclic compounds | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222129-A1 | Non-imidazole heterocyclic compounds | HRH3, HRH4, HRH2 | HRH3 1/4885ALDH1A1 2417/4885NPSR1 303/4885 |
| US-20080317671-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | HRH3, HRH4, HRH2 | HRH3 1/4885ALDH1A1 2417/4885NPSR1 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.